Acute Lymphoblastic Leukemia With Failed Remission
10
6
6
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
20.0%
2 terminated out of 10 trials
33.3%
-53.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Efficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
Determining the Mechanisms of Loss of CAR T Cell Persistence
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia